Discovery of a Phenylalanine‐Derived Natural Compound as a Potential Dual Inhibitor of MDM2 and MDMX
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500397 ↗At a glance
Journal article in ChemMedChem, 2025. Written by Ja Young Cho and 5 co-authors. Institution: Prokaryote Research Division, Nakdonggang National Institute of Biological Resources (NNIBR), Sangju, 37242, Republic of Korea. Major MEDLINE topics: Proto-Oncogene Proteins c-mdm2, Phenylalanine, Antineoplastic Agents, Biological Products. Cited 2 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministry of Environment (MOE) of the Republic of Korea.
Abstract (original language)
Dual inhibition of the negative p53 regulators MDM2 and MDMX has emerged as an effective strategy in p53‐based anticancer therapy. However, dual inhibitors are limited, and many inhibitors exhibit poor pharmacokinetic properties and fast dissociation kinetics. Among newly identified microbial metabolites, the novel phenylalanine‐derived compound P5 isolated from Micromonospora sp. MS‐62 (FBCC‐B8445) exhibits inhibitory activity against both MDM2 and MDMX. The binding of P5 to MDM2 and MDMX is demonstrated by surface plasmon resonance, which reveals nanomolar‐level affinity and slow dissociation kinetics (KD = 46 nM for MDM2; 576 nM for MDMX). This dual inhibitory activity was further supported by molecular docking, which reveals binding of P5 to the p53‐binding pockets of both MDM2 and MDMX through extensive noncovalent interactions. In cell‐based assays, P5 reduced cancer cell viability across several human cell lines. Furthermore, in silico analysis indicates favorable pharmacokinetic properties, including gastrointestinal absorption, blood–brain barrier permeability, and compliance with Lipinski's and Veber's criteria. P5 combines dual‐target engagement with binding persistence and favorable pharmacokinetic characteristics, addressing limitations of earlier inhibitors. P5 is a potential lead compound for the development of MDM2/MDMX‐targeted anticancer agents.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Prokaryote Research Division, Nakdonggang National Institute of Biological Resources (NNIBR), Sangju, 37242, Republic of Korea.
- Bio-resources Bank Division, Nakdonggang National Institute of Biological Resources (NNIBR), Sangju, 37242, Republic of Korea.
- Institute of Natural Products, Korea Institute of Science and Technology (KIST), Gangneung, 25451, Republic of Korea.
- Department of Oceanography, Kunsan National University, Gunsan, 54150, Republic of Korea.
- Research division for Biotechnology, Advanced Radiation Technology Institute (ARTI), Korea Atomic Energy Research Institute (KAERI), Jeongeup, 56212, Republic of Korea.
ORCID profiles: Ja Young Cho, Jung-Rae Rho, Hyoung-Woo Bai
Funding
- Ministry of Environment (MOE) of the Republic of Korea
Cite
APA
Cho, J. Y., Park, S., Kim, T., Eom, J., Rho, J. R., & Bai, H. W. (2025). Discovery of a Phenylalanine‐Derived Natural Compound as a Potential Dual Inhibitor of MDM2 and MDMX. ChemMedChem. https://doi.org/10.1002/cmdc.202500397
Vancouver
Cho JY, Park S, Kim T, Eom J, Rho JR, Bai HW. Discovery of a Phenylalanine‐Derived Natural Compound as a Potential Dual Inhibitor of MDM2 and MDMX. ChemMedChem. 2025. doi:10.1002/cmdc.202500397
BibTeX
@article{Cho2025,
author = {Cho, Ja Young and Park, Sanghwa and Kim, Taejung and Eom, Junghye and Rho, Jung-Rae and Bai, Hyoung-Woo},
title = {Discovery of a Phenylalanine‐Derived Natural Compound as a Potential Dual Inhibitor of MDM2 and MDMX},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500397}
}
EUVIMED